Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2017-12-19 Report Publication Anno…
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Datum:19.12.2017
Report Publication Announcement Classification · 1% confidence The document is a short notification (under 1,000 characters) titled 'Hinweis auf Jahresfinanzbericht' (Notice regarding the Annual Financial Report). It provides the location (URL) where the actual report can be accessed and the date of publication. Per the 'Menu vs Meal' rule, since this is an announcement of a report's availability rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2017-12-19 German
4SC receives milestone payment from Immunic
Regulatory Filings Classification · 1% confidence The document is a short press release dated December 13, 2017, announcing that 4SC AG received a milestone payment from Immunic AG related to a previous sale of an immunology portfolio. It contains standard press release formatting, including a headline, date, boilerplate about the issuer being responsible for content, and contact information. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it is a general corporate announcement disseminated via a news service (DGAP), and it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Dividend (DIV), the most appropriate general category for a corporate news item that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous announcements.
2017-12-13 English
4SC AG: Significant milestone reached for pivotal RESMAIN study of resminostat as maintenance therapy in CTCL
Regulatory Filings Classification · 1% confidence The document is a press release dated December 5, 2017, originating from 4SC AG, disseminated via DGAP. It announces a significant milestone (patient enrollment progress) in a pivotal clinical study (RESMAIN) for a drug candidate (resminostat) and provides an expected timeline for top-line results (H1 2019). This content is typical of a corporate update regarding clinical trial progress, which is not explicitly covered by the core financial filings (10-K, IR, ER, MRQ). It is a general corporate news announcement concerning R&D progress. Since it is not a formal financial report, a management change, a dividend notice, or a specific regulatory filing like a Director's Dealing or Proxy Statement, the most appropriate classification is the general regulatory announcement/news category, which is RNS (Regulatory Filings) as per the provided definitions, acting as a catch-all for significant corporate news that doesn't fit elsewhere.
2017-12-05 English
DGAP-DD: 4SC AG english
Director's Dealing Classification · 1% confidence The document explicitly uses the header "Directors’ Dealings" and contains detailed information regarding a transaction (Acquisition of Shares) by a person discharging managerial responsibilities (Dr. Clemens Doppler, Member of the administrative or supervisory body). This directly matches the definition for Director's Dealing reports.
2017-12-04 English
DGAP-DD: 4SC AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the transaction (Acquisition of Shares) by a specific individual (Dr. Manfred Rüdiger) who is a 'Member of the administrative or supervisory body' of 4SC AG. This content directly matches the definition for Director's Dealing, which corresponds to the filing code DIRS.
2017-11-07 English
First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma
Regulatory Filings Classification · 1% confidence The document is a press release dated November 6, 2017, announcing a corporate update regarding clinical trial progress ('First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma'). It uses keywords like 'DGAP-News', 'Press release ends', and provides contact information and boilerplate legal disclaimers typical of corporate news wires. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement of operational/clinical progress. Since it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), and it is a general corporate news item distributed via a service (DGAP), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered elsewhere, especially those distributed via news services.
2017-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.